US 12,331,084 B2
Multivalent OspA polypeptides and methods and uses relating thereto
Urban Lundberg, Pressbaum (AT); Andreas Meinke, Pressbaum (AT); Abhijeet Nayak, Amsterdam (NL); and Wolfgang Schüler, Vienna (AT)
Assigned to Valneva Austria GmbH, Vienna (AT)
Filed by Valneva Austria GmbH, Vienna (AT)
Filed on May 15, 2024, as Appl. No. 18/665,018.
Application 18/665,018 is a continuation of application No. 16/497,178, granted, now 12,018,054, previously published as PCT/EP2018/059533, filed on Apr. 13, 2018.
Claims priority of application No. 17166483 (EP), filed on Apr. 13, 2017.
Prior Publication US 2025/0101069 A1, Mar. 27, 2025
Int. Cl. A61K 39/39 (2006.01); A61K 39/02 (2006.01); A61P 31/04 (2006.01); C07K 14/20 (2006.01); A61K 39/00 (2006.01)
CPC C07K 14/20 (2013.01) [A61K 39/0225 (2013.01); A61K 39/39 (2013.01); A61P 31/04 (2018.01); A61K 2039/55505 (2013.01); A61K 2039/575 (2013.01); A61K 2039/70 (2013.01); C07K 2319/02 (2013.01); C07K 2319/90 (2013.01)] 20 Claims
 
1. A nucleic acid molecule encoding an immunogenic polypeptide comprising a C-terminal domain of an outer surface protein A (OspA) of Borrelia, characterized in that said C-terminal OspA domain comprises at least three specific OspA epitopes each from distinct Borrelia strains causing Lyme Borreliosis; wherein said C-terminal OspA domain is able to induce a protective immune response to all of said distinct Borrelia strains, wherein the C-terminal OspA domain is selected from the group consisting of SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 12, SEQ ID NO: 13, and immunogenic variants thereof that have at least 95% sequence identity with any one of SEQ ID NO:9, SEQ ID NO: 10, SEQ ID NO: 12, or SEQ ID NO: 13, and wherein a three-dimensional structure of the C-terminal OspA domain is stabilized by introduction of at least two cysteine residues that form a disulfide bond.